DOWNLOAD THIS SLIDE KIT

• Simplifying second-line treatment from double-boosted PI therapy to LPV/r monotherapy allows for sustain virologic suppression in the majority of children after 48 weeks of follow-up

• 50 HIV-1 infected Thaï children failing first line NRTIs + NNRTI, switched to double ritonavir-boosted PIs for 144 weeks (LPV/r + SQV = 90%) ; 40 children with virological suppression (HIV-1 RNA < 50 c/mL at least 3 months apart) switched to LPV/r 230/57.5 mg/m2 bid monotherapy
• Female: 50%, Median age: 11.7 years
• At W48
  • HIV-1 RNA < 50 c/mL: 72.5%
  • Still on LPV/r monotherapy, N = 31 (78%)
  • Returned to double boosted PIs due to failure, N = 9
  • No emergence of major protease resistance mutations